Jefferies Group reaffirmed their hold rating on shares of Opko Health Inc. (NYSE:OPK) in a research note published on Monday. The firm currently has a $10.00 price target on the stock.

A number of other analysts have also issued reports on OPK. Deutsche Bank AG dropped their price target on shares of Opko Health from $11.00 to $10.00 and set a hold rating for the company in a research note on Thursday, June 16th. Oppenheimer Holdings Inc. restated a hold rating on shares of Opko Health in a research note on Thursday, June 16th. Standpoint Research lifted their price objective on shares of Opko Health from $16.00 to $18.00 and gave the stock a buy rating in a report on Tuesday, June 21st. Zacks Investment Research downgraded shares of Opko Health from a hold rating to a sell rating in a report on Friday, July 1st. Finally, JPMorgan Chase & Co. set a $14.00 price objective on shares of Opko Health and gave the stock a buy rating in a report on Tuesday, August 9th. Five analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has an average rating of Buy and a consensus target price of $13.20.

Analyst Recommendations for Opko Health (NYSE:OPK)

Shares of Opko Health (NYSE:OPK) traded down 1.61% during trading on Monday, reaching $9.79. 584,268 shares of the company’s stock were exchanged. Opko Health has a 52 week low of $7.12 and a 52 week high of $11.85. The company’s 50-day moving average is $10.06 and its 200 day moving average is $10.09. The stock has a market capitalization of $5.39 billion and a PE ratio of 40.96.

Opko Health (NYSE:OPK) last issued its quarterly earnings results on Monday, August 8th. The company reported $0.02 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.05. The company earned $357.10 million during the quarter, compared to the consensus estimate of $324.11 million. The firm’s quarterly revenue was up 742.2% on a year-over-year basis. During the same quarter last year, the firm posted ($0.09) EPS. On average, analysts forecast that Opko Health will post ($0.05) earnings per share for the current year.

In other Opko Health news, CEO Phillip Md Et Al Frost purchased 10,000 shares of the company’s stock in a transaction on Wednesday, July 27th. The shares were purchased at an average cost of $9.91 per share, for a total transaction of $99,100.00. Following the completion of the transaction, the chief executive officer now owns 3,068,951 shares in the company, valued at $30,413,304.41. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Hedge funds have recently bought and sold shares of the company. Janus Capital Management LLC increased its stake in Opko Health by 0.6% in the second quarter. Janus Capital Management LLC now owns 15,800 shares of the company’s stock valued at $148,000 after buying an additional 100 shares during the last quarter. Metropolitan Life Insurance Co. NY increased its stake in Opko Health by 1.2% in the second quarter. Metropolitan Life Insurance Co. NY now owns 22,945 shares of the company’s stock valued at $214,000 after buying an additional 261 shares during the last quarter. Gilman Hill Asset Management LLC increased its stake in Opko Health by 0.6% in the second quarter. Gilman Hill Asset Management LLC now owns 46,661 shares of the company’s stock valued at $436,000 after buying an additional 298 shares during the last quarter. Public Employees Retirement Association of Colorado increased its stake in Opko Health by 0.8% in the second quarter. Public Employees Retirement Association of Colorado now owns 77,228 shares of the company’s stock valued at $721,000 after buying an additional 612 shares during the last quarter. Finally, Moors & Cabot Inc. increased its stake in Opko Health by 2.3% in the second quarter. Moors & Cabot Inc. now owns 61,100 shares of the company’s stock valued at $571,000 after buying an additional 1,350 shares during the last quarter.

Opko Health Company Profile

OPKO Health, Inc (OPKO) is a healthcare company. The Company operates through two segments: diagnostics and pharmaceutical. The pharmaceutical segment consists of its pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain, and its pharmaceutical research and development operations. The diagnostics segment primarily consists of its clinical laboratory operations.

5 Day Chart for NYSE:OPK

Receive News & Stock Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related stocks with our FREE daily email newsletter.